Novo Nordisk Weighs MASH Evidence Against a Billion-Dollar Legal Hangover

Novo Nordisk faces dual catalysts: promising Semaglutide MASH analyses at EASL and an unresolved $800M legal dispute with KBP Biosciences, as stock recovers but remains down 13% YTD.

Novo Nordisk is navigating two very different bets on the second quarter. One hinges on a Singapore asset freeze and a New York arbitration panel; the other on how well Semaglutide performs in a liver that is not yet cirrhotic. Neither has delivered a final verdict, but both will colour the stock’s trajectory as the company tries to convince investors that its best days are not behind it.

The Danish drugmaker will present fresh analyses from the ESSENCE programme at the European Association for the Study of the Liver (EASL) congress in Barcelona between May 27 and 30. The data package covers liver safety in MASH patients taking Semaglutide 2.4 mg, along with subgroup results for Japanese patients and postmenopausal women, and real-world evidence on disease burden and treatment costs. The US Food and Drug Administration has already cleared Wegovy for MASH in adults with moderate to severe fibrosis under an accelerated pathway, but the company needs to confirm clinical benefit on hard endpoints such as death, liver transplant and decompensation. Interim data from the pivotal trial showed 63% of Wegovy patients achieved MASH resolution without worsening of fibrosis, versus 34% on placebo; fibrosis improvement without MASH deterioration was 37% against 22%. Those figures support the view that Semaglutide can modify liver disease, not merely reduce weight.

While the scientific community pores over those numbers, a separate legal battle continues to simmer. The Singapore Court of Appeal on May 21 upheld a worldwide asset freeze against KBP Biosciences and its founder, Zhenhua Huang. Novo Nordisk had sought the injunction after paying $700 million in October 2023 for Ocedurenone, a hypertension drug candidate that later failed a Phase 3 interim analysis. A further $100 million sits in escrow. The company has written off more than $800 million on the deal and alleges that the positive Phase 2 data relied almost entirely on results from a single Bulgarian study centre whose findings were anomalous. KBP denies the claims, and the court stressed it has made no final finding of fraud or dishonesty. The injunction merely preserves the status quo until the substantive dispute is resolved under New York law. No timetable has been set for the arbitration award, and a monetary recovery for Novo Nordisk is far from guaranteed.

The convergence of a data catalyst and an unresolved liability comes at a delicate time for the stock. Shares have traded around €38.86 recently, recovering about 16% over the past month but still down roughly 13% year to date. At one point they had lost almost half their value from the 52-week high of €70.13. First-quarter results, reported in early May, showed adjusted operating profit of 32.9 billion Danish kroner, a 6% decline at constant exchange rates. Revenue and operating profit for the full year are each expected to drop by 4% to 12%, even after the company raised its guidance on stronger GLP-1 sales. The obesity business remains the brightest spot, with adjusted growth of 22% in the quarter, but the broader top-line weakness reflects the absence of one-off US effects that flattered prior comparisons.

MASH offers an adjacent market that overlaps directly with obesity and type 2 diabetes, the two conditions that have turned Wegovy and Ozempic into blockbusters. If ESSENCE delivers a convincing safety and efficacy narrative, it could help lengthen the platform’s commercial runway. But the KBP fallout is a reminder that not every acquisition pays off, and that Novo Nordisk’s dealmaking discipline is under scrutiny as much as its R&D engine. The next major inflection point lies with the New York arbitration panel, where the fight over Ocedurenone will finally be settled — if not in time to lift this year’s earnings, then at least to remove an overhang that has hung over the stock since the write-down.